After losing patent protection on their osteoporosis drug Actonel, Ireland-based Warner Chilcott is restructuring its E.U. operations and plans to cut 500 jobs in the process, according to Fierce Pharma. Actonel brought in about 70% of Warner's sales in Western Europe in 2010, and the drug is up against generic competition.
Warner will restructure its business in Belgium, the Netherlands, France, Germany, Italy, Spain, Switzerland and the U.K. However, commercial operations in the U.K. and Germany will not be affected, nor will its headquarters in Dublin.
The cutbacks will allow Warner to focus on the U.S., where it's launching an osteoporosis remedy and an oral contraceptive, Hans van Zoonen, president of Warner's European and international operations, said in a statement. "The restructuring initiative will allow us to focus on growth opportunities that match Warner Chilcott's key competitive strengths, including the launches of Atelvia and Lo Loestrin Fe in the United States," said van Zoonen, who's also president of global marketing.